US Market News
7 일 전
The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in ParallelJuly 6, 2026 8:45 AM
PR Newswire (US) A wave of government funding, hardware progress, and looming encryption deadlines has turned quantum from a lab curiosity into one of the most closely watched corners of the market in 2026, spanning computing hardware and the cybersecurity built to survive it.VANCOUVER, BC, July 6, 2026 /PRNewswire/ -- USA News Group News Commentary, For years, quantum computing lived mostly in research papers and conference keynotes. In 2026 it has become something harder to ignore: a sector with federal capital behind it, a string of technical milestones on the board, and a parallel race to rebuild the world's encryption before quantum machines can break it. The result is one of the most polarizing themes in the market, real scientific progress on one side, valuations that assume a commercial payoff still years away on the other. Below is a look at where the sector stands and a handful of the public companies operating across its very different lanes, from computing hardware to post-quantum security, including QSE - Quantum Secure Encryption Corp. (CSE: QSE) (OTCQB: QSEGF) (FSE: VN8). Key TakeawaysWashington has moved from rhetoric to capital, with the U.S. Department of Commerce announcing roughly $2 billion in quantum funding under the CHIPS and Science Act in May 2026, followed by a pair of executive orders on June 22, 2026 setting hard agency timelines for quantum hardware and cryptographic defense.The pure-play computing names, including IonQ, Rigetti, and D-Wave, pursue fundamentally different architectures, while big-cap programs at IBM and Alphabet carry the frontier with far deeper balance sheets.A separate but related lane, post-quantum security, is racing against fixed regulatory deadlines as organizations prepare to migrate encryption before quantum machines can break it.Names operating across these lanes include QSE - Quantum Secure Encryption Corp. (CSE: QSE), IonQ (NYSE: IONQ), Rigetti Computing (Nasdaq: RGTI), D-Wave Quantum (NYSE: QBTS), and IBM (NYSE: IBM), each distinct, each at a different scale, and none a proxy for any other.Washington Puts Money Behind the ThemeThe clearest signal that quantum has moved from speculation toward strategic priority came from the federal government. In May 2026, the U.S. Department of Commerce announced approximately $2 billion in funding for the quantum industry under the CHIPS and Science Act, with several companies set to receive direct funds in exchange for equity stakes. The announcement sent quantum stocks sharply higher across the board, even for companies not named as direct recipients.The following month, on June 22, 2026, a pair of executive orders turned that broad funding narrative into a structured federal timeline. One directive targets national quantum computing and sensing capabilities, coordinating multiple agencies to deliver a science-enabling quantum computer to a Department of Energy facility later this decade. A second focuses on cryptographic defense, directing federal agencies to begin migrating high-value systems to post-quantum cryptography. For a sector where nearly every pure-play company still burns cash, the alignment of federal policy behind its success has put a floor under valuations that pure speculation never could.The Computing Race: Different Bets on the Same FutureOne fact matters more than any single stock: no one yet knows which quantum architecture will scale best. That uncertainty is the defining feature of the sector, and it is why the public companies pursuing quantum computing look so different from one another.IonQ (NYSE: IONQ) is the largest pure-play by revenue and the name many institutions reach for first. It builds trapped-ion systems prized for high fidelity and long qubit coherence, and it has pushed into quantum networking as a hedge on where near-term revenue may come from. Its business rests on hardware plus partnerships with major cloud platforms and government programs.Rigetti Computing (Nasdaq: RGTI) takes the superconducting path, building modular chips optimized for scalability and selling access to its systems through the cloud. The company has pursued a government-contract-first strategy and signed a letter of intent with the Department of Commerce for a proposed award of up to $100 million over three years under the CHIPS Act build-out.D-Wave Quantum (NYSE: QBTS) occupies a distinct position, having built its business on quantum annealing, a specialized technique well suited to optimization problems rather than universal gate-based computing. It has more recently added a gate-model platform, giving it two fundamentally different approaches under one roof.IBM (NYSE: IBM) and Alphabet (Nasdaq: GOOGL) anchor the big-cap end of the field, where quantum is upside rather than survival. IBM has published one of the most detailed roadmaps in the industry, targeting a demonstration of quantum advantage by the end of 2026 and a large-scale, fault-tolerant system it calls Starling by 2029. Alphabet's Google Quantum AI drew wide attention with error-correction progress on its Willow chip. Both carry the balance sheets to keep pushing regardless of near-term commercial results.The Other Half of the Story: Securing the Quantum EraRunning alongside the computing race is a second, less flashy contest with a firmer deadline: replacing the encryption that protects nearly all sensitive data today before quantum machines grow powerful enough to break it. The concern is not hypothetical. Security researchers describe a "harvest now, decrypt later" dynamic, in which encrypted data is captured today on the expectation it can be unlocked once the technology matures.The regulatory calendar has sharpened that concern. In August 2024, the National Institute of Standards and Technology finalized its first three post-quantum cryptography standards, and the U.S. National Security Agency's CNSA 2.0 framework sets a phased timeline for national security systems to adopt quantum-safe algorithms over the balance of the decade. Those deadlines have turned what was long a strategy-document abstraction into an operational project for enterprises and governments alike.That is the lane QSE - Quantum Secure Encryption Corp. (CSE: QSE) (OTCQB: QSEGF) (FSE: VN8) operates in. The Canadian company describes itself as a post-quantum cybersecurity firm focused on quantum-resilient data protection, identity security, secure storage, and cryptographic migration readiness. In March 2026 it launched QPA v2, an enterprise platform designed to help organizations assess where their encryption is exposed, inventory cryptographic dependencies, and plan a migration to quantum-safe standards. Other names positioned across the post-quantum security stack include established security vendors and specialists such as Arqit Quantum (Nasdaq: ARQQ), alongside larger platform players. As with the computing names, these companies operate at very different scales and pursue different models.The Case for CautionFor all the momentum, the quantum sector remains among the most speculative corners of the market. The industry still operates in what researchers call the NISQ era, noisy intermediate-scale quantum, where today's leading systems top out in the low hundreds to low thousands of physical qubits and require aggressive error correction. There is still no commercial killer application running at scale on quantum hardware, and useful chemistry, cryptography, and optimization workloads at scale remain a late-decade story by most estimates.The financial profile reflects that. Pure-play quantum companies trade at extreme valuations relative to minimal revenue, regularly raise equity to fund research, and expose shareholders to dilution and steep volatility. Architectures can go obsolete if a rival reaches fault-tolerance first. Government funding has put a floor under the sector, but policy is a tailwind, not a guarantee, and execution against technical roadmaps remains the ultimate test. For most risk-aware investors, the takeaway from the analysts covering the space is consistent: treat quantum as a small, diversified, long-horizon position rather than a sure thing.The Bottom LineQuantum in 2026 is a sector finally backed by real money and real milestones, and still years from proving its commercial thesis. The computing names are placing different architectural bets on the same uncertain future, the big-cap programs are funding the frontier, and a parallel security race is running against fixed deadlines that do not depend on any single company succeeding. For investors watching the theme, the sector rewards breadth and patience over conviction in any one name, and the next checkpoints, hardware milestones, funded roadmaps hitting their dates, and enterprise adoption of post-quantum tools, are the markers worth watching from here.SIGNAL OVER NOISESignal over noise. Quantum-computing and cybersecurity headlines move fast, and the crowd often moves first. Eagle Eye is a real-time investor signal-intelligence platform that surfaces sentiment shifts, news flow, and trending tickers as they happen, so you see the move forming instead of reading about it later. See it at eagle-eye.dev.CONTACTUSA News Group
info@usanewsgroup.comSOURCES[1] U.S. Department of Commerce quantum funding under the CHIPS and Science Act, announced May 2026; contemporaneous market coverage, 2026.
[2] Executive orders on national quantum capabilities and cryptographic defense, signed June 22, 2026; contemporaneous coverage, 2026.
[3] IBM Quantum roadmap and corporate disclosures, 2025-2026.
[4] QSE - Quantum Secure Encryption Corp. (CSE: QSE), corporate disclosures and news releases, 2026, including the QPA v2 launch dated March 31, 2026.
[5] IonQ, Inc. (NYSE: IONQ); Rigetti Computing, Inc. (Nasdaq: RGTI); D-Wave Quantum Inc. (NYSE: QBTS); Arqit Quantum Inc. (Nasdaq: ARQQ), corporate disclosures and market data, 2026.DISCLAIMERNothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. This article is being distributed for Market IQ Media Group Limited, a company incorporated under the laws of Ireland ("MIQL"), which wholly owns and operates USA News Group. MIQL has previously been paid a fee for QSE - Quantum Secure Encryption Corp. advertising and digital media, which fee has since expired. There may be 3rd parties who may have shares of QSE - Quantum Secure Encryption Corp., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constituted a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. MIQL and its owner/operators own shares of QSE - Quantum Secure Encryption Corp. acquired through private placement and in the open market, and reserve the right to buy and sell shares of QSE - Quantum Secure Encryption Corp. at any time without any further notice commencing immediately and ongoing. This article is a general overview of the quantum technology sector and is intended for informational and industry-context purposes only. None of the companies named in this article, including QSE - Quantum Secure Encryption Corp., has reviewed, approved, endorsed, commissioned, or is responsible for the content of this article, and nothing herein should be construed as a statement by, or on behalf of, any company mentioned. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. All references to companies named in this article are based on those companies' public disclosures, are provided for industry context only, and do not imply any partnership, endorsement, affiliation, or comparable performance.FORWARD-LOOKING STATEMENTS: This publication contains forward-looking statements, including statements regarding the growth of the quantum computing and post-quantum security sectors; government funding and policy timelines; the technology roadmaps, milestones, and commercial prospects of the companies referenced; and the pace of enterprise and government adoption of quantum-safe cryptography. Forward-looking statements are based on current expectations and assumptions and are subject to known and unknown risks and uncertainties, many beyond any company's control, including the technical difficulty of scaling quantum hardware and achieving fault tolerance; the risk that a given architecture is superseded; the substantial capital requirements and dilution risk facing early-stage companies; uncertain timing and terms of government funding; competition from larger and better-capitalized companies; and the pace at which regulatory deadlines translate into commercial demand. Actual results could differ materially from those projected. References to other companies are based on those companies' public disclosures, are provided for industry context only, and do not imply any partnership, endorsement, affiliation, or comparable performance. Except as required by law, none of the companies referenced undertakes any obligation to update any forward-looking statement. View original content to download multimedia:https://www.prnewswire.com/news-releases/the-quantum-sector-hits-an-inflection-point-federal-money-real-milestones-and-a-security-race-running-in-parallel-302818222.html Original: The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in Parallel
US Market News
7 일 전
As AI Models Become Commodities, a Bio-Native AI Company Just Moved to Patent the Data Layer Beneath the ModelsJuly 6, 2026 8:55 AM
PR Newswire (Canada) Issued on behalf of MindWalk Holdings Corp.MindWalk Holdings Corp. (NASDAQ: HYFT) filed a European patent application directed to the high-dimensional biological data architecture beneath its HYFT® Technology, ReefIQ™, and LensAI™, the model-agnostic context layer designed to let AI models and agentic workflows retrieve, compare, and reason over connected, traceable biology in drug discovery.AUSTIN, Texas, July 6, 2026 /CNW/ -- USA News Group News Commentary — A growing consensus in artificial intelligence holds that the models themselves are becoming interchangeable, and that durable advantage is migrating away from the model and toward the proprietary, structured data a model reasons over. On that thesis, MindWalk Holdings Corp. (NASDAQ: HYFT), a Bio-Native AI company, has filed a European patent application directed to the high-dimensional data structures at the core of its HYFT® Technology, moving to protect the enriched biological data layer that its commercial platforms are designed to run on. Key TakeawaysMindWalk Holdings Corp. (NASDAQ: HYFT) filed European patent application No. EP26187897.9, directed to high-dimensional data structures for biological subsequences and property inference, intended to protect the enriched biological representation architecture beneath its HYFT® Technology, ReefIQ™ biological context layer, and LensAI™ reasoning workflows.The filing rests on a thesis gaining traction across life-sciences AI: as frontier models trend toward commodity, durable advantage migrates to the data layer, the structured, domain-specific representation that lets any model or agent retrieve, compare, and reason over biology with traceable context.The application is described as additive to MindWalk's foundational HYFT patent (WO 2020/161344), protecting a distinct computational layer built on the original foundation rather than a re-filing of it, and anchoring a market where spending on AI in drug discovery is projected to grow from roughly US$5 billion in 2026 to more than US$8 billion by 2030, atop more than US$250 billion in annual pharmaceutical R&D.MindWalk is advancing amid broader activity in AI-enabled life sciences, a landscape that includes public names investors track such as Absci (NASDAQ: ABSI), Certara (NASDAQ: CERT), AstraZeneca (NASDAQ: AZN), and NVIDIA (NASDAQ: NVDA), each distinct, and none a proxy for MindWalk.Patenting the Layer Beneath the ModelThe premise behind the filing is that in artificial intelligence, the models are becoming easier to substitute. As frontier systems from competing labs converge on similar capabilities, MindWalk argues the place where lasting advantage accrues is shifting away from the model and toward the proprietary, structured data the model is given to reason over. On June 2026, the Austin-based Bio-Native AI company announced it filed European patent application No. EP26187897.9, directed to high-dimensional data structures for biological subsequences and property inference. The application is intended to protect the enriched biological representation architecture that underpins its HYFT® Technology, its ReefIQ™ biological context layer, and its LensAI™ reasoning workflows."Every AI model eventually becomes easier to substitute; the durable question is what biological context the model runs on," said Jennifer Bath, Ph.D., Chief Executive Officer and President of MindWalk. "In life sciences, the differentiator is not a generic chatbot layer, but the structured representation that lets models and agentic workflows retrieve connected evidence, preserve provenance, and reuse knowledge across programs. This filing is intended to protect aspects of the architecture at the core of HYFT® Technology, where MindWalk believes lasting value in biological AI can compound."The company frames the timing against a clear architectural lesson emerging in agentic AI for life sciences: frontier models alone are not enough. It points to recent public work on scientific agents, including NVIDIA's BioNeMo Agent Toolkit and AstraZeneca's ChatInvent system, as evidence of the need for domain-specific context, structured tool interfaces, provenance, memory, and validation when AI agents are deployed in real scientific workflows.An Additive Layer, Not a Re-FilingThe new application builds on MindWalk's foundational HYFT patent (WO 2020/161344), which established how the company identifies characteristic biological patterns that recur across life and uses them as a searchable language to compare sequences without alignment. According to MindWalk, EP26187897.9 protects a distinct and additive layer, organizing the biological meaning around those patterns into a form that can be reused across the company's infrastructure, customer programs, and AI workflows. The company describes it as the computational layer built on the original foundation, not a re-filing of it.The contrast the company draws with a model-only approach is central to its argument. Large language models are powerful, MindWalk notes, but their learned knowledge is largely embedded in model parameters and can be difficult to inspect, update, or govern in a biological discovery setting. Its architecture is designed to add a separate, biology-aware representation layer that keeps meaningful biological patterns connected to sequence-level, structural, physicochemical, functional, experimental, and literature-derived context in a form that can be retrieved, compared, updated, and reused across workflows, evolving as new biological knowledge is generated rather than requiring every insight to be absorbed into a new model-training cycle.The work targets a persistent obstacle in drug discovery: fragmented data. A single program may generate sequence information, structural context, physicochemical signals, assay results, literature evidence, and historical decisions across different systems and teams. When that context is scattered, MindWalk argues, scientists and AI systems lose information that should remain connected, and the company's architecture is designed instead to keep each meaningful biological pattern tied to the context that explains why it matters."Biology does not live in one file type," said Dirk Van Hyfte, M.D., Ph.D., Chief Technology Officer of MindWalk. "Sequence, structure, physicochemical behavior, function, evidence, and literature all need to stay connected for AI systems to be useful in discovery. Through this filing, we are seeking to protect the layer that keeps those biological connections organized, accessible, and usable as discovery work moves between AI models, software tools, and human scientific teams."From Architecture to Active ProgramsMindWalk says it has begun to demonstrate the approach in active programs, with results the company is careful to frame as preclinical. In dengue, the company has reported preclinical binding-level data in which a HYFT®-identified target informed immunogen design and generated antibodies that bound across antigens from all four dengue serotypes in two independent campaigns. In influenza, MindWalk has disclosed a HYFT®-defined functional constraint observed across broad influenza A and B datasets, including human, avian, swine-associated, Victoria, and Yamagata backgrounds. These programs remain preclinical, and the company states that additional studies are required to assess neutralization, safety, durability, clinical translation, regulatory path, and commercial potential.The approach reflects what MindWalk calls its functional and evolutionary-constraint thesis: that recurring biological patterns often persist because they are tied to function, structure, binding, immune recognition, or evolutionary fitness. By representing those patterns together with their surrounding context, the company aims to give AI systems a more organized and traceable basis for reasoning over biology.The Commercial Layer and Why It Matters to InvestorsReefIQ™ and LensAI™ are the commercial expression of this representation strategy. The company states that LensAI™ is in contracted, recurring arrangements with life-sciences customers today, and that the filing is intended to protect a layer those deployments can build on as data and program experience accumulate. In MindWalk's framing of the stack, HYFT® identifies biologically meaningful pattern anchors, ReefIQ™ organizes customer and program data around those anchors as governed biological context, and LensAI™ operates over that context to support target discovery, candidate diligence, hypothesis generation, and portfolio decision support.That data layer also anchors a large and growing market. By the company's cited third-party estimates, spending on AI in drug discovery is projected to grow from approximately US$5 billion in 2026 to more than US$8 billion by 2030, atop the more than US$250 billion the pharmaceutical industry invests in research and development each year. Those figures are third-party projections that may prove inaccurate, and the company presents them as context. For investors, MindWalk frames the filing as support for a strategy of building value beyond any single AI model, with the durable asset being the biology-aware representation layer itself, a model-agnostic infrastructure asset the company believes can become more valuable as more programs, evidence, and customer data are connected to it.The Public Companies Around AI-Enabled Drug DiscoveryMindWalk is a Bio-Native AI company pursuing an infrastructure strategy and is not directly comparable to the names below. These comparisons are for industry context only; each company pursues a different technology and business model, several are far larger or further along, and none is a proxy for MindWalk or implies any partnership or comparable performance.Absci (NASDAQ: ABSI) is a clinical-stage biopharmaceutical company that applies generative AI and synthetic biology to design antibody therapeutics, pairing AI models with high-throughput wet-lab validation. Absci illustrates the AI-native, model-plus-wet-lab end of drug discovery, a different approach to the shared goal of making AI useful in real biological workflows.Certara (NASDAQ: CERT) provides biosimulation and model-informed drug-development software used across pharmaceutical R&D. As an established software-and-services provider to drug developers, Certara offers a view of the software-infrastructure layer of the industry that platform-stage companies are working within.AstraZeneca (NASDAQ: AZN), a global biopharmaceutical company, has publicly detailed agentic-AI work in discovery, including the ChatInvent system referenced in connection with MindWalk's filing. AstraZeneca represents the large-pharma end of the spectrum, where major developers are building and deploying agentic AI inside real discovery workflows.NVIDIA (NASDAQ: NVDA) supplies much of the compute and software infrastructure behind modern AI, including life-sciences tools such as its BioNeMo Agent Toolkit referenced in connection with the filing. NVIDIA illustrates the compute-and-tooling foundation on which AI-enabled discovery, including the kind of agentic workflows MindWalk describes, is being built.The Bottom LineA patent application is a beginning, not a guarantee. European examination can narrow or reject claims, and the scope, issuance, enforceability, and competitive value of any patent that ultimately issues remain open questions the company itself flags, alongside the preclinical status of its dengue and influenza programs. But the strategic signal is coherent: in a world where AI models are trending toward commodity, MindWalk is betting that lasting value in life-sciences AI lives in the structured biological data underneath, and it is moving to protect its version of that layer at the architectural root. For investors tracking where durable advantage accrues as the AI buildout matures, MindWalk's filing is a concrete data point, with the patent's prosecution, customer adoption, and revenue trajectory the markers worth watching from here.SIGNAL OVER NOISESignal over noise. Biotech, artificial-intelligence, and drug-discovery headlines move fast, and the crowd often moves first. Eagle Eye is a real-time investor signal-intelligence platform that surfaces sentiment shifts, news flow, and trending tickers as they happen, so you see the move forming instead of reading about it later. See it at eagle-eye.dev.CONTACTUSA News Group
info@usanewsgroup.comSOURCES[1] MindWalk Holdings Corp., "MindWalk (NASDAQ: HYFT) Files Patent for High-Dimensional Biological Data Architecture Powering AI Drug Discovery" (Business Wire, AUSTIN, Texas, 2026; European patent application No. EP26187897.9; HYFT®, ReefIQ™, LensAI™; foundational HYFT patent WO 2020/161344).[2] Absci Corporation (NASDAQ: ABSI), corporate and clinical disclosures, 2026.[3] Certara, Inc. (NASDAQ: CERT), corporate disclosures, 2026.[4] AstraZeneca PLC (NASDAQ: AZN), corporate disclosures; ChatInvent agentic system described in He J, Lai H, Saigiridharan L, Ghiandoni GM, et al., "Democratising real-world drug discovery through agentic AI," Drug Discovery Today, 2026.[5] NVIDIA Corporation (NASDAQ: NVDA), corporate disclosures; BioNeMo Agent Toolkit, NVIDIA Developer Blog, 2026.[6] AI-in-drug-discovery market estimates (Fortune Business Insights; Astute Analytica) and pharmaceutical R&D spending (Fierce Biotech; Statista), cited for context.DISCLAIMERNothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. This article is being distributed by USA News Group on behalf of Market IQ Media Group Limited, a company incorporated under the laws of Ireland ("MIQL"). MIQL has been paid a fee for MindWalk Holdings Corp. advertising and digital media from Creative Direct Marketing Group ("CDMG"). There may be 3rd parties who may have shares of MindWalk Holdings Corp., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. MIQL and its owner/operators do not own any shares of MindWalk Holdings Corp., but reserve the right to buy and sell shares of MindWalk Holdings Corp. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQL has been reviewed and approved on behalf of MindWalk Holdings Corp. by CDMG. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.FORWARD-LOOKING STATEMENTS: This publication contains forward-looking statements, including statements regarding European patent application No. EP26187897.9 and the prosecution, scope, issuance, enforceability, and competitive value of any patent that may issue; the possibility that claims may be narrowed, rejected, or successfully challenged; the role of the patented architecture in HYFT® Technology, ReefIQ™, the biological representation, and the LensAI™ platform; risks that preclinical results described, including the dengue binding-level data and the influenza functional-constraint findings, may not be reproduced and may not translate into neutralization, safety, efficacy, durability, or clinical or commercial success, and that these programs remain preclinical and subject to substantial further study; the size, growth, and addressability of the markets referenced, which are based on third-party estimates that may prove inaccurate; the pace and degree of customer and market adoption; the technical performance of AI-based discovery methods; competition; regulatory determinations; and capital-markets conditions. Additional information is available in MindWalk's Annual Report on Form 20-F and other filings on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov/edgar). Except as required by law, MindWalk undertakes no obligation to update any forward-looking statement. References to other companies are based on those companies' public disclosures, are provided for industry context only, and do not imply any partnership, endorsement, affiliation, or comparable performance. HYFT® is a registered trademark, and LensAI™ and ReefIQ™ are trademarks, of MindWalk Holdings Corp. or its subsidiaries.Logo - https://mma.prnewswire.com/media/2838876/5656770/USA_News_Group_Logo.jpg View original content:https://www.prnewswire.com/news-releases/as-ai-models-become-commodities-a-bio-native-ai-company-just-moved-to-patent-the-data-layer-beneath-the-models-302818260.html Original: As AI Models Become Commodities, a Bio-Native AI Company Just Moved to Patent the Data Layer Beneath the Models
US Market News
4 주 전
The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath ItJune 16, 2026 8:45 AM
PR Newswire (US) Issued on behalf of MindWalk Holdings Corp.Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.NEW YORK, June 16, 2026 /PRNewswire/ -- Equity Insider News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, models that can predict how a protein folds or design an antibody from scratch. But a quieter and increasingly influential argument is taking hold among the people actually building these systems: in biology, the model may be the least durable part of the equation. Models improve, get copied, and get commoditized. What is hard — and potentially far more valuable — is the connected, trustworthy biological knowledge the model has to reason over in the first place. Feed even a brilliant model fragmented, contradictory data and it will, in the words of one industry executive, confidently get it wrong. That debate moves to center stage on June 15, 2026, when MindWalk Holdings Corp. (NASDAQ: HYFT) joins a virtual investor panel hosted by research firm Jones — alongside generative-biology company Absci (NASDAQ: ABSI) and a leading AI compute provider — titled "Partnering to Power the New Era of Drug Discovery." The panel is a small event, but it sits on top of one of the most consequential questions in biotech: as the industry pours capital into AI, what is the part that actually compounds in value? MindWalk's answer — and the trajectory of the broader field — is worth understanding now, because it reframes where the durable advantages in AI-driven medicine may ultimately lie.Why AI Drug Discovery Hit a Wall — and What ChangedThe promise of applying AI to drug discovery has always been intoxicating: compress the decade-plus, billion-dollar odyssey of finding and validating a new medicine into something faster, cheaper, and more likely to succeed. The early wave of "AI-first" biotechs raised enormous sums on that promise. But the field ran into a hard truth that has little to do with algorithms. Biological data is a mess. It is scattered across incompatible files, formats, instruments, lab notebooks, and decades of literature; it is riddled with gaps and contradictions; and the relationships that matter most — how a sequence maps to a structure, a function, a mechanism, a disease — are often implicit rather than recorded. A model trained or prompted on that fragmented foundation can produce fluent, confident answers that are simply wrong, a failure mode the field has come to call hallucination.In consumer applications, a hallucinating chatbot is an annoyance. In drug discovery, it is a multimillion-dollar wrong turn, sending scientists down a path toward a target or molecule that was never viable. As the industry now races to deploy not just static AI models but autonomous "agentic" systems — AI that can plan and execute multi-step research workflows with limited human supervision — the cost of bad underlying data multiplies. An agent acting on fragmented biology does not just give one wrong answer; it compounds the error across an entire chain of decisions. That escalating risk is exactly why attention is shifting from the models themselves to the integrity of the biological foundation they operate on.MindWalk's Bet: Own the Context Layer, Not the ModelMindWalk — a company that rebranded in 2025 from its prior identity as ImmunoPrecise Antibodies, unifying its operations and adopting the Nasdaq ticker HYFT — has built its entire strategy around that shift. Rather than competing to build the flashiest model, the company positions its durable asset as the layer underneath: a biological "context layer" that connects and enriches data before any model reasons over it. Its proprietary HYFT® Technology, refined over roughly two decades of curation, is described as a continuously evolving biological representation spanning 660 million biological patterns and 25 billion relationships — a kind of connective tissue that links sequences, structures, functions, mechanisms, pathways, evidence, and literature into a single queryable foundation.On top of that foundation sit two products the company has brought to market. ReefIQ™, launched in June 2026, is pitched as the biological context layer that sits between a client's fragmented discovery data and its AI reasoning workflows — reconnecting the pieces before the AI acts. LensAI™ is the reasoning and application layer used for target discovery, candidate diligence, and portfolio decision support, and increasingly to host the agentic workflows pharma is racing to adopt. The company's central thesis, which CEO Dr. Jennifer Bath is expected to articulate on the Jones panel, is that because its predictions are grounded in what evolution has already conserved — the functional patterns that have survived across biology — rather than in raw statistical correlation, the system is designed to keep both models and agents from hallucinating in the highest-consequence workflows. Bath has framed the convergence she sees as "biology, context, and compute."Importantly, this is not purely conceptual. MindWalk reported that its largest enterprise AI client signed a one-year LensAI platform contract — the first contracted, recurring platform-revenue agreement in the company's history — and that the structure is one it intends to scale across its client base. For its fiscal third quarter ended January 31, 2026, the company reported revenue of $4.2 million (in Canadian dollars), up 52% year-over-year and a third consecutive quarter of year-over-year growth, with U.S. revenue doubling. The company also reported preclinical dengue data that, by its account, supported a computational prediction its platform generated before any animal was immunized — an early, real-world validation of the approach.The Field Around MindWalkMindWalk is one expression of a sector that has matured well beyond the first hype cycle, and looking at how a few public peers are positioned helps frame both the opportunity and where MindWalk's niche sits within it. Each of these companies attacks the AI-drug-discovery problem from a different layer of the stack.Absci Corporation (NASDAQ: ABSI) — MindWalk's fellow panelist — represents the generative-design frontier. The company uses generative AI models paired with an integrated wet lab to design therapeutic antibodies essentially from scratch, conditioning its models on a target's structure and then validating proposals through high-throughput experiments. Absci became clinical-stage with an AI-designed antibody entering a Phase 1 trial, making it a closely watched proof point for whether generative design can produce real drugs. It illustrates the "design" layer of the field — complementary to the data-foundation layer MindWalk emphasizes.Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is among the largest and best-known "AI-first" drug discovery platforms, having industrialized the generation of biological data through massive automated experimentation and paired it with machine learning to identify drug candidates. With collaborations involving major pharmaceutical companies and its own clinical-stage pipeline, Recursion represents the scaled, full-stack ambition of the sector — building both the data engine and the drug pipeline — and the patient capital that strategy requires.Schrödinger, Inc. (NASDAQ: SDGR) approaches the problem from a different intellectual tradition: physics-based computational chemistry. Its software platform simulates how molecules behave at a fundamental level to predict which candidates are worth pursuing, and it both licenses that software to the industry and advances its own pipeline. Schrödinger illustrates the established, software-led end of the field — a reminder that "computational drug discovery" predates the current AI wave and that different modeling philosophies coexist and compete.Certara, Inc. (NASDAQ: CERT) rounds out the group as the infrastructure-and-decision-support comparison closest in spirit to MindWalk's positioning. A leader in biosimulation and model-informed drug development, Certara provides software and AI-powered services used across the drug-development lifecycle, including in regulatory submissions. As one of the more established, revenue-generating names in the space, it demonstrates that there is a durable, infrastructure-layer business in AI-enabled drug development — the same category MindWalk is targeting with its context layer, albeit at a far larger and more mature scale. These companies are referenced to illustrate the sector and do not imply any partnership, endorsement, affiliation, or comparable financial performance; they differ widely in approach, size, and stage, and MindWalk is among the smaller, earlier-stage names. References to Absci, Jones, and the other panelists describe the event only and do not imply any endorsement or commercial relationship.The Investment Case — and the RisksThe bull case for the context-layer thesis is conceptually elegant. If models are destined to commoditize — and the pace at which capable AI models now proliferate suggests they might — then the enduring value in AI drug discovery accrues to whoever owns the trusted, connected biological foundation that every model and agent must rely on. A context layer, in that telling, becomes infrastructure: something pharma rents rather than rebuilds, with recurring revenue and compounding value as more data and more programs run through it. MindWalk's first recurring platform contract and its growing revenue are early evidence that customers may be willing to pay for exactly that.The risks, however, are substantial and should not be minimized. MindWalk is a small-cap company still posting operating losses as it transitions from a legacy wet-lab services business toward a scalable platform model. Its revenue, while growing, is modest in absolute terms, and the company depends on converting engagement into contracted, recurring arrangements that have only just begun. It relies on third-party compute and cloud providers, faces intense competition from larger and better-funded players, and operates in a field where adoption of bio-native and agentic AI could prove slower than hoped. As with any clinical- or platform-stage life-sciences company, there is no certainty that the capabilities described will translate into commercial success, and forward-looking claims about the technology remain just that — forward-looking.A Sector Finding Its Real FoundationWhat makes this moment interesting is not any single company or any single panel. It is that the AI-drug-discovery field appears to be maturing past its first, model-obsessed phase into a more sophisticated understanding of where value actually lives. The lesson emerging from the first wave — that pointing powerful AI at messy biology produces confident nonsense — has pushed serious players toward the unglamorous but essential work of connecting and grounding biological knowledge. Whether the durable advantage ultimately sits in generative design, industrialized data generation, physics-based simulation, or a connected context layer is precisely the question a panel like the one on June 15 exists to debate.MindWalk has placed a clear, focused bet on the context layer — that in the age of agentic AI, the biology has to be connected and trustworthy before a model ever acts on it, and that owning that foundation is the durable prize. It is an early-stage bet, with real execution and financing risk, and the market has yet to render its verdict. But the trajectory of the field is unmistakable: the conversation has moved from "whose model is biggest" toward "whose biology is most trustworthy," and the companies building that foundation are positioning themselves at what may prove to be the most defensible layer of the entire AI-medicine stack. For investors trying to understand where the next decade of drug discovery is headed, that shift is the story worth watching.SEE WHAT THE MARKET IS TALKING ABOUT BEFORE IT MOVESEagle Eye reads social, forum, and news chatter across thousands of investor conversations in real time — and surfaces the tickers the crowd is piling into, along with the sentiment and catalysts behind them.Explore Eagle Eye free (for now) at https://Eagle-Eye.devCONTACT:Equity Insiderinfo @therooster-2873SOURCES:[1] MindWalk Holdings Corp. — "MindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel…" (Business Wire, June 12, 2026; primary source for the panel, HYFT/ReefIQ/LensAI platform, Bath quote, 660M patterns / 25B relationships):
https://finance.yahoo.com/sectors/healthcare/articles/mindwalk-nasdaq-hyft-ceo-dr-130000157.html[2] MindWalk Holdings Corp. — "Launches ReefIQ™, a Biological Context Layer for AI Drug Discovery" (Business Wire, June 10, 2026; ReefIQ context-layer detail):
https://www.businesswire.com/news/home/20260610294167/en/MindWalk-Holdings-Corp.-NASDAQ-HYFT-Launches-ReefIQ-a-Biological-Context-Layer-for-AI-Drug-Discovery[3] MindWalk Holdings Corp. — "Reports Q3 Fiscal 2026 Financial Results" (Business Wire, March 12, 2026; $4.2M revenue +52% YoY, first recurring LensAI contract, subsidiaries):
https://www.businesswire.com/news/home/20260312858299/en/MindWalk-Holdings-Corp.-Reports-Q3-Fiscal-2026-Financial-Results[4] MindWalk Holdings Corp. — "ImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to 'HYFT'" (Business Wire, Sept 3, 2025; rebrand, platform business-model shift):
https://www.businesswire.com/news/home/20250903938726/en/ImmunoPrecise-Rebrands-as-MindWalk-Announces-NASDAQ-Ticker-Change-to-HYFT[5] BioPharmaTrend — "Publicly Traded AI-driven Drug Discovery Companies" and related sector coverage (peer context: Absci, Recursion, Schrödinger, Certara):
https://www.biopharmatrend.com/artificial-intelligence/recent-ipos-among-ai-driven-platforms-for-drug-discovery-and-biotech-601/DISCLAIMER:Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a digital media distribution and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances.Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). This article is being distributed by Equity Insider on behalf of MIQ. MIQ has been paid a fee for MindWalk Holdings Corp. advertising and digital media from Creative Direct Marketing Group ("CDMG"). This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this article or email as the basis for any investment decision. MIQ does not own shares of MindWalk Holdings Corp. but reserves the right to buy and sell shares of MindWalk Holdings Corp. at any time without any further notice. There may be 3rd parties who may have shares of MindWalk Holdings Corp., and may liquidate their shares which could have a negative effect on the price of the stock. We also expect further compensation as an ongoing digital media effort to increase visibility for the company; no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been reviewed and approved on behalf of MindWalk Holdings Corp. by CDMG; this is a digital media distribution.While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our publication is not trustworthy unless verified by their own independent research. Comparisons to other companies referenced in this publication are for contextual and illustrative purposes only and do not imply any partnership, endorsement, affiliation, or comparable financial performance. References to the Jones AI Day panel, Absci, and other panelists describe the event only and do not imply any endorsement, sponsorship, partnership, or commercial relationship. Forward-looking statements regarding technology, platform adoption, recurring revenue, clinical and preclinical outcomes, and market trends are subject to risks and uncertainties, and actual results may differ materially. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. View original content to download multimedia:https://www.prnewswire.com/news-releases/the-quiet-bottleneck-in-ai-drug-discovery-isnt-the-model--its-the-biology-underneath-it-302800965.html Original: The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It
US Market News
2 월 전
Altasciences et Certara annoncent un partenariat stratégique visant à accélérer le développement de médicaments en phase précoceMay 7, 2026 8:16 PM
Business Wire Altasciences , une organisation proposant des solutions de développement de médicaments pleinement intégrées, et Certara (Nasdaq : CERT), leader mondial du développement de médicaments fondé sur des modèles (MIDD), ont annoncé aujourd'hui la conclusion d'un partenariat stratégique visant à accélérer les programmes de développement en phase précoce. Moins de la moitié des candidats médicaments précliniques parviennent à passer le cap des premiers essais cliniques chez l'humain. Les échecs sont principalement dus à la toxicité, à une pharmacocinétique défavorable, à un manque d'efficacité et aux difficultés rencontrées pour transposer à l'homme des résultats obtenus sur des animaux. Bon nombre de ces risques peuvent être atténués grâce à une approche de développement de médicaments pleinement intégrée et fondée sur des modèles. S'appuyant sur la plateforme d'accélération d'Altasciences, l’intégration des services de développement stratégique de médicaments et de la technologie de biosimulation de Certara permet aux sponsors d’établir plus rapidement la preuve de concept, de concevoir des études plus efficaces et de prendre des décisions éclairées quant au lancement ou à l'abandon de l'essai en plus grande confiance. En intégrant les données de modélisation et les workflows numériques directement à l’exécution du développement, les plans d’étude sont optimisés, les stratégies posologiques évoluent et les programmes sont mieux intégrés aux services non cliniques, cliniques, bioanalytiques et de production. « Chez Altasciences, nous aidons déjà les sponsors à passer rapidement de la première évaluation de sécurité à la validation de principe de manière rapide et précise », a déclaré Marie-Hélène Raigneau, CEO d’Altasciences. « En intégrant les capacités de modélisation de Certara à notre plateforme, nous pouvons éclairer davantage les décisions critiques, plus tôt et avec une plus grande assurance. Cette collaboration vise à réduire l’incertitude aux moments les plus importants. » Ce partenariat arrive à point nommé, alors que la FDA continue de promouvoir de nouvelles orientations en faveur d'approches de développement de médicaments plus adaptatives, fondées sur les données et en temps réel : des capacités que les modèles d'exécution MIDD intégrés peuvent parfaitement fournir. « Ce partenariat ouvre de nouvelles perspectives pour faciliter les décisions relatives au développement précoce chez les sponsors de biotechnologies et leurs investisseurs », a déclaré Jon Resnick, CEO de Certara. « En intégrant la modélisation et la simulation directement à l'exécution, nous permettons une prise de décision plus rapide et plus éclairée, ce qui, en fin de compte, profite aux patients. » Ensemble, Altasciences et Certara font progresser une approche du développement précoce de médicaments, axée sur la modélisation, entièrement intégrée et économe en ressources qui accélère le processus de validation de principe pour les innovateurs en biotechnologie, les investisseurs et les laboratoires pharmaceutiques du monde entier. À propos d'Altasciences Altasciences est une société de solutions de développement pharmaceutique intégrées qui propose aux entreprises pharmaceutiques et biotechnologiques une approche éprouvée et flexible pour leurs programmes d'études précliniques et cliniques, notamment la formulation, la fabrication et les services analytiques. Depuis plus de 30 ans, Altasciences collabore avec les sponsors pour les aider à prendre des décisions éclairées, plus rapides et plus complètes en matière de développement précoce de médicaments. Les solutions intégrées et complètes d'Altasciences comprennent les essais de sécurité précliniques, la pharmacologie clinique et la validation de principe, la bioanalyse, la gestion de programmes, la rédaction médicale, la biostatistique et la gestion des données. Elles sont entièrement personnalisables selon les besoins spécifiques des sponsors. Altasciences aide les sponsors à mettre plus rapidement des médicaments plus efficaces à la disposition des patients qui en ont besoin. À propos de Certara Certara accélère le développement de médicaments grâce à des logiciels, des technologies et des services de modélisation, transformant ainsi les méthodes traditionnelles de découverte et de développement pharmaceutiques. Parmi ses clients figurent plus de 2 600 entreprises biopharmaceutiques, institutions universitaires et organismes de réglementation répartis dans 70 pays. Rendez-vous sur www.certara.com. Le texte du communiqué issu d’une traduction ne doit d’aucune manière être considéré comme officiel. La seule version du communiqué qui fasse foi est celle du communiqué dans sa langue d’origine. La traduction devra toujours être confrontée au texte source, qui fera jurisprudence. Consultez la version source sur businesswire.com : https://www.businesswire.com/news/home/20260507024608/fr/ Julie-Ann Cabana
Altasciences
media@altasciences.com Original: Altasciences et Certara annoncent un partenariat stratégique visant à accélérer le développement de médicaments en phase précoce
US Market News
2 월 전
Altasciences und Certara kündigen strategische Partnerschaft zur Beschleunigung der frühen Phase der Arzneimittelentwicklung anMay 7, 2026 8:17 PM
Business Wire Altasciences , ein vollständig integriertes Unternehmen für Arzneimittelentwicklungslösungen, und Certara (Nasdaq: CERT),, ein Weltmarktführer im Bereich modellgestützte Arzneimittelentwicklung (Model-Informed Drug Development, MIDD), haben heute eine strategische Partnerschaft bekannt gegeben, in deren Rahmen sie Entwicklungsprogramme in der Frühphase beschleunigen wollen. Weniger als die Hälfte der präklinischen Wirkstoffkandidaten schafft es erfolgreich bis zu ersten Studien am Menschen. Ursachen für das Scheitern sind Toxizität, ungünstige Pharmakokinetik, mangelnde Wirksamkeit sowie Schwierigkeiten bei der Übertragung der Ergebnisse aus Tierversuchen auf den Menschen. Viele dieser Risiken können durch einen vollständig integrierten, modellgestützten Ansatz in der Wirkstoffentwicklung minimiert werden. Die auf der Acceleration Platform von Altasciences aufbauende Integration der strategischen Dienstleistungen zur Arzneimittelentwicklung und der Biosimulationstechnologie von Certara ermöglicht es Auftraggebern, früher einen Wirkmechanismusnachweis zu erbringen, effizientere Studiendesigns zu entwerfen und fundierte Go/No-Go-Entscheidungen mit größerer Sicherheit zu treffen. Durch die direkteEinbindung von Modellierungserkenntnissen und digitalen Arbeitsabläufen in die Entwicklungsdurchführung können Studiendesigns optimiert, Dosierungsstrategien verfeinert und Programme nahtloser über nichtklinische, klinische, bioanalytische und herstellungstechnische Dienstleistungen hinweg integriert werden. „Bei Altasciences unterstützen wir Auftraggeber bereits heute dabei, schnell und präzise von der ersten Sicherheitsbewertung bis hin zum Konzeptnachweis zu gelangen“, so Marie-Hélène Raigneau, CEO von Altasciences. „Durch die Einbindung der Modellierungsfunktionen von Certara in unsere Plattform können wir noch früher und mit größerer Sicherheit Informationen für wichtige Entscheidungen bereitstellen. Ziel dieser Zusammenarbeit ist es, Unsicherheiten in den entscheidenden Momenten zu verringern.“ Die Partnerschaft wird zu einem günstigen Zeitpunkt eingegangen, da die FDA weiter neue Leitlinien zur Förderung adaptiverer, datengestützter und in Echtzeit erfolgender Ansätze in der Arzneimittelentwicklung vorantreibt – Fähigkeiten, für deren Umsetzung integrierte MIDD-Ausführungsmodelle bestens aufgestellt sind. „Diese Partnerschaft erschließt neue Möglichkeiten zur Verbesserung früher Entwicklungsentscheidungen für Biotech-Auftraggeber und ihre Investoren“, so Jon Resnick, CEO von Certara. „Indem wir Modellierung und Simulation direkt in die Umsetzung einbetten, ermöglichen wir eine schnellere und fundiertere Entscheidungsfindung, von der letzten Endes die Patienten profitieren.“ Altasciences und Certara treiben gemeinsam einen modellorientierten, vollständig integrierten und ressourceneffizienten Ansatz für die frühe Arzneimittelentwicklung voran, der den Weg zum Konzeptnachweis für Biotech-Innovatoren, Investoren und Pharmaunternehmen weltweit beschleunigt. Über Altasciences Altasciences ist ein Unternehmen für integrierte Arzneimittelentwicklungslösungen, das Pharma- und Biotechnologieunternehmen einen bewährten, flexiblen Ansatz für präklinische und klinische Studienprogramme bietet, einschließlich Formulierungs-, Herstellungs- und Analysedienstleistungen. Altasciences arbeitet seit über 30 Jahren mit Auftraggebern zusammen, um fundierte, schnellere und umfassendere Entscheidungen in der frühen Phase der Arzneimittelentwicklung zu unterstützen. Die integrierten Full-Service-Lösungen des Unternehmens umfassen präklinische Sicherheitsprüfungen, klinische Pharmakologie und Konzeptnachweis, Bioanalytik, Programmmanagement, Medical Writing, Biostatistik und Datenmanagement, die alle an die spezifischen Anforderungen der jeweiligen Auftraggeber angepasst werden können. Altasciences unterstützt seine Auftraggeber bei der schnelleren Bereitstellung besserer Medikamente für die Menschen, die sie benötigen. Über Certara Certara beschleunigt die Entwicklung von Arzneimitteln mithilfe von Biosimulationssoftware, Technologie und Dienstleistungen, um die traditionelle Arzneimittelforschung und -entwicklung zu transformieren. Zu den Kunden von Certara zählen mehr als 2.600 biopharmazeutische Unternehmen, akademische Einrichtungen und Zulassungsbehörden in 70 Ländern. Besuchen Sie uns unter www.certara.com. Die Ausgangssprache, in der der Originaltext veröffentlicht wird, ist die offizielle und autorisierte Version. Übersetzungen werden zur besseren Verständigung mitgeliefert. Nur die Sprachversion, die im Original veröffentlicht wurde, ist rechtsgültig. Gleichen Sie deshalb Übersetzungen mit der originalen Sprachversion der Veröffentlichung ab. Originalversion auf businesswire.com ansehen: https://www.businesswire.com/news/home/20260507437848/de/ Julie-Ann Cabana
Altasciences
media@altasciences.com Original: Altasciences und Certara kündigen strategische Partnerschaft zur Beschleunigung der frühen Phase der Arzneimittelentwicklung an
Hot Features
프리미엄
무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
iHub News
6 일 전
Insight01
2 월 전
